Background

Fresenius Kabi SwissBioSim, a company of the Fresenius Kabi Group, inaugurates its new global research and development center in the field of biosimilars in Eysins (Vaud). At the forefront of research on biosimilar drugs, the Fresenius Group subsidiary intends to consolidate its leadership in this field, thanks to a strategic location in the heart of the “Health Valley” of the Lake Geneva region.

While biosimilars have the potential to help control rising healthcare costs and represent an opportunity to make advanced therapies affordable for patients with critical or chronic conditions, these medicines are still largely unknown to the public.